A necklace, wristband and bodycam helped researchers reveal five hidden overeating styles that could shape the future of obesity treatment.
Rebel Wilson joins Noom as chief wellness ambassador, backing its new free tier that gamifies healthy habits and spotlights microdose GLP-1s.
FuturHealth, a provider of weight-loss solutions including GLP-1s, will offer Apple Fitness+ at no additional cost to its members.
Hims & Hers' Dr. Craig Primack explains why personalized care, not just GLP-1s, is the key to lasting weight loss success.
Syntis Bio has raised $38M to advance its injectable-free, once-daily pill that mimics gastric bypass surgery.
Northwestern researchers developed an open-source algorithm that improves fitness tracker accuracy for people with obesity.
Veracity secures $6M from Maveron and Melitas Ventures to grow its metabolic health platform, including its best-selling Metabolism Ignite.
New research from links modest, nonpharmacological weight loss in midlife to lower long-term risks of chronic disease and early death.
Hims & Hers and Novo Nordisk are teaming to expand affordable access to weight loss treatments, launching a bundled Wegovy offering.
New data shows U.S. consumer spending on GLP-1 drugs like Ozempic, Wegovy and Mounjaro soared from $13.7B to $71.7B between 2018 and 2023.
Sign Up to Our Newsletter
